ABCL
insider transactionsAbCellera Biologics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 3 different insiders made open-market purchases in the last 365 days, totalling $952.1K.
Net shares · 365d
+278.1K
278.1K buy · 0 sell
Net value · 365d
$952.1K
$952.1K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
4
278.1K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
111.7K sh
Own +11%
-
Grant·A
Director
$0
111.7K sh
Own +57%
-
Grant·A
Director
$0
111.7K sh
Own +12%
-
Exercise·M
Andrew Booth KEY
Chief Financial Officer
$0
250.0K sh
Own +3%
-
Exercise·M
Andrew Booth KEY
Chief Financial Officer
$47.5K
250.0K sh · $0.19
Own +128%
-
Buy·P
Director
$95.4K
20.0K sh · $4.77
Own +9%
-
Buy·P
10% Owner
$130.7K
38.0K sh · $3.44
Own +0%
-
Buy·P
Andrew Booth KEY
Chief Financial Officer
$145.7K
42.6K sh · $3.42
Own +28%
-
Buy·P
10% Owner
$580.3K
177.5K sh · $3.27
Own +0%
-
Grant·A
Chief Legal Officer
$0
539.3K sh
Own +13%
-
Grant·A
Chief Technology Officer
$0
539.3K sh
Own +12%
-
Grant·A
Chief Executive Officer
$0
2.1M sh
Own +19%
-
Grant·A
Andrew Booth KEY
Chief Financial Officer
$0
808.9K sh
Own +10%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | John S. Montalbano | Grant A | 111.7K | $0 |
| Jun 11, 2026 | Stephen Quake | Grant A | 111.7K | $0 |
| Jun 11, 2026 | Michael R Hayden | Grant A | 111.7K | $0 |
| Jun 3, 2026 | Andrew Booth KEY | Exercise M | 250.0K | $0 |
| Jun 3, 2026 | Andrew Booth KEY | Exercise M | 250.0K | $47.5K |
| May 14, 2026 | John S. Montalbano | Buy P | 20.0K | $95.4K |
| Feb 27, 2026 | Thermopylae Holdings Ltd. | Buy P | 38.0K | $130.7K |
| Feb 27, 2026 | Andrew Booth KEY | Buy P | 42.6K | $145.7K |
| Feb 26, 2026 | Thermopylae Holdings Ltd. | Buy P | 177.5K | $580.3K |
| Jan 1, 2026 | Tryn Stimart | Grant A | 539.3K | $0 |
| Jan 1, 2026 | Veronique Lecault | Grant A | 539.3K | $0 |
| Jan 1, 2026 | Carl L. G. Hansen KEY | Grant A | 2.1M | $0 |
| Jan 1, 2026 | Andrew Booth KEY | Grant A | 808.9K | $0 |
About ABCL insider trading
This page tracks insider transactions for AbCellera Biologics Inc. (ABCL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.